Rivaroxaban
- PDF / 169,206 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 29 Downloads / 148 Views
1 S
Bleeding: case report In a retrospective clinical study of 12 patients treated between September 2015 and November 2018, a patient [age and sex not stated] was described; who developed slight bleeding during treatment with rivaroxaban for the prevention of thromboembolic events in non-valvular atrial fibrillation. The patient received treatment with direct oral anticoagulant rivaroxaban [Xarelto] 20mg per day, dose taken at night for at least six months before implant placement. The patient interrupted the medication for 24 hour and received implants and immediate restorations. The patient experienced slight bleeding associated with rivaroxaban. A mechanical compression with gauzes was applied to control the bleeding. The patient required an additional compression with tranexamic acid and the bleeding was controlled. No major complications were noted. Galletti G, et al. Implant placement in patients under treatment with rivaroxaban: A retrospective clinical study. International Journal of Environmental Research and Public 803498914 Health 17: 1-13, No. 12, Jun 2020. Available from: URL: http://doi.org/10.3390/ijerph17124607
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
